Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC

NCT00981799 is registered in ClinicalTrials.gov with Therapeutic Advances in Childhood Leukemia Consortium as lead sponsor.

NCT NCT00981799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00981799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2010
Completion date
July 18, 2016
Enrollment
23 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed t-cell acute lymphoblastic leukemia, relapsed t-cell lymphoblastic lymphoma